Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of CPI-613 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane) for Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT03435289 is registered in ClinicalTrials.gov with Atlantic Health System as lead sponsor.

NCT NCT03435289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03435289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of CPI-613 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane) for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Atlantic Health System
Phase
Phase 1
Overall status
Unknown status
Start date
October 19, 2017
Completion date
January 31, 2019
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, pancreatic cancer